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Q Are oral emergency  
contraceptives a safe & effective 
form of long-term birth control?
EVIDENCE-BASED ANSWER
A Yes, but not as effective as some  other methods. Annual pregnancy 
rates in women using pericoital levonor- 
gestrel 150 mcg to 1 mg range from 4.9% 
to 8.9%; menstrual irregularity is the most 
common adverse effect (strength of rec-
ommendation [SOR]: B, Cochrane review 
of lower-quality trials). 
In women younger than 35 years who 
have sexual intercourse 6 or fewer times 
per month, correct and consistent use of 
pericoital levonorgestrel 1.5 mg results in 
an annual pregnancy rate of 11% (SOR: B, 
one large prospective, open-label trial). 
Pericoital contraception is less ef-
fective than long-acting reversible con-
traceptives (annual pregnancy rates of 
0.05%-0.8%) or perfect use of combined 
oral contraceptives (0.3% annual preg-
nancy rate), but similar to, or better than, 
typical use of combined oral contraception 
(9%) and condoms (18%). 
Evidence summary
A systematic review of 22 trials (13 case se-
ries, 8 prospective, nonrandomized stud-
ies, and one randomized controlled trial; 
12,407 patients) conducted in Europe, Asia, 
and the Americas evaluated the likelihood of 
pregnancy with repeated use of precoital and 
postcoital hormonal contraception.1 Some 
trials used more than one dose or medica-
tion. Many had inadequate reporting of re-
search methods. Results were reported using 
the Pearl Index (PI)—the number of pregnan-
cies per 100 woman-years. 
In 11 studies (2700 patients), women 
took 750 mcg of levonorgestrel from 24 hours 
before to 24 hours after intercourse for an 
average duration of 5 cycles or months. Co-
ital frequency varied from 1 to 15 times per 
month. The PI ranged from 0 to 18.6, with a 
pooled PI of 5.4 (95% confidence interval 
[CI], 4.1-7.0). Three of the trials (915 patients), 
with research methods reported as good, had 
a pooled PI of 8.9 (95% CI, 5.1-14.4). No seri-
ous adverse effects were reported in 10 of the 
11 studies, but menstrual irregularity was 
commonly observed. In one of the largest 
studies (1315 patients), only 3% of women 
discontinued treatment because of adverse 
effects. 
Six other trials (5785 patients) of le-
vonorgestrel taken at doses ranging from 
150 mcg to 1 mg for a mean duration of 
9.2 cycles reported PIs of 0 to 9. Breakthrough 
bleeding was the most common adverse 
event. When all 17 studies of levonorgestrel 
were combined, the PI was 4.9 (95% CI, 4.3-
5.5). The remaining studies in the systematic 
review described medicines not commonly 
used for emergency contraception or not 
available in the United States.
Other reported adverse effects:  
Headache, nausea, abdominal pain
A prospective, open-label study enrolled 
321 women 18 to 45 years of age from Asia, Eu-
rope, and South America to evaluate the safety 
and efficacy of levonorgestrel 1.5 mg taken 
before or within 24 hours of intercourse as the 
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exclusive means of contraception.2 Women 
who were lactating or recently postpartum 
were excluded; condoms were permitted 
for women who had concerns about risk of 
sexually transmitted illness. Data analysis in- 
cluded estimates of perfect use (consistent 
and correct use of levonorgestrel only) and 
typical use (use of other contraceptive meth-
ods in addition to levonorgestrel). 
At baseline, weight, blood pressure, and 
hemoglobin were documented, and follow-
up visits occurred at 2.5, 4.5, and 6.5 months. 
Pregnancy tests, blood pressure, and adverse 
effects were assessed at each visit; weight and 
hemoglobin were evaluated at the final visit. 
The primary outcome measure was the PI in 
women younger than 35 years who used only 
levonorgestrel for contraception. 
In women younger than 35 years 
(208 patients), the PI was 11 (95% CI, 5.7-13.1) 
with perfect use and 10.3 (95% CI, 5.4-19.9) 
with typical use. In all ages 18 to 45 years, the 
PI was 7.1 (95% CI, 3.8-13.1) for typical use 
and 7.5 (95% CI, 4-13.9) for perfect use. Most 
women took 4 to 6 doses per month. 
The most commonly reported adverse 
effects were headache (29%), nausea or ab-
dominal pain (16%), influenza (11%), and 
acne or candidiasis (8%). Bleeding patterns 
varied with a tendency toward longer bleed-
ing initially and lighter menstrual periods 
and less anemia in some patients at the end 
of the study.
Recommendations
The Office of Population Research at Princ-
eton University suggests that moderate re-
peat use of emergency contraceptives is 
unlikely to cause serious harm, but estimates 
that women using progestin-only emergency 
contraception on a regular basis would have 
a 20% chance of pregnancy in a year.3 
The American College of Obstetricians 
and Gynecologists states that long-term use 
of emergency contraception is less effective 
than other methods and may result in higher 
hormone levels and more adverse effects 
than other established means.4
The International Consortium for Emer-
gency Contraception concluded that there is 
no basis for limiting the number of times that 
emergency contraceptives may be used in a 
menstrual cycle, that emergency contracep-
tives are safe, and that, although they are less 
effective than other forms of long-term con-
traception, using them repeatedly is more ef-
fective than using no method.5
The Society of Obstetricians and Gyne-
cologists of Canada states that emergency 
contraception is intended for occasional use 
as a backup method.6 The Society also notes 
that repeat use isn’t as effective as regular use 
of other forms of contraception.
The Faculty of Sexual & Reproductive 
Healthcare of the (British) Royal College of 
Obstetricians and Gynaecologists says that 
use of levonorgestrel can be considered 
even if previously used one or more times 
in a menstrual cycle (SOR: D, based on non- 
analytical studies and expert opinion).7 The 
organization also recommends that emer-
gency contraceptive providers share with 
patients that oral emergency contraceptive 
methods should not be used for long-term 
contraception (SOR: Good Practice Point, 
based on clinical experience of the guideline 
development group). 
The Guttmacher Institute reports that 
without contraception, approximately 85% 
of sexually active women become pregnant 
each year.8 Long-acting reversible methods, 
such as implants and intrauterine devices, 
have annual pregnancy rates of 0.05% to 
0.8%. With perfect (consistent and correct) 
use, combined oral contraceptives have a 
0.3% annual pregnancy rate, but the rate rises 
to 9% with typical use. Condoms, when used 
perfectly, are associated with a 2% annual 
rate of pregnancy compared with an 18% rate 
with typical use.                  JFP
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